PSMA-PET/CT and Ultrasound Fusion: PSMA-PET/CT can specifically identify the molecularly metabolically active regions of prostate cancer lesions, while ultrasound offers real-time anatomical guidance. This evidence concerns the gene FOLH1 and Familial prostate cancer.